

INVIVO THERAPEUTICS HOLDINGS CORP.

Form SC TO-I/A

May 20, 2013

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

**SCHEDULE TO**

**(Rule 14d-100)**

**TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1)**

**OF THE SECURITIES EXCHANGE ACT OF 1934**

**(Amendment No. 4)**

**INVIVO THERAPEUTICS HOLDINGS CORP.**

**(Name of Subject Company (Issuer))**

**INVIVO THERAPEUTICS HOLDINGS CORP. (Issuer)**

**(Name of Filing Persons (Identifying status as offeror, issuer or other person))**

**Warrants to Purchase Common Stock dated October 26, 2010**

**Investor Warrants to Purchase Common Stock**

**Placement Agent Warrants to Purchase Common Stock**

**(Title of Class of Securities)**

**N/A**

**(CUSIP Number of Class of Securities)**

Edgar Filing: INVIVO THERAPEUTICS HOLDINGS CORP. - Form SC TO-I/A

**Frank Reynolds**

**Chief Executive Officer**

**InVivo Therapeutics Holdings Corp.**

**One Kendall Square, Suite B14402**

**Cambridge, Massachusetts 02139**

**Phone: (617) 863-5500**

(Name, address, and telephone numbers of person authorized to receive notices and communications on behalf of filing persons)

*With copies to:*

**Bradley Jacobson, Esq.**

**Greenberg Traurig, LLP**

**One International Place**

**Boston, Massachusetts 02110**

**Phone: (617) 310-6205**

**Facsimile: (617) ) 279-8402**

**CALCULATION OF FILING FEE**

**Transaction Valuation\***  
\$14,284,044

**Amount of Filing Fee**  
\$1,948.35

\* The transaction value is estimated for solely for purposes of calculating the amount of the filing fee. The calculation assumes that all eligible warrants to purchase 15,009,608 shares of the Issuer's common stock subject to the offer will be exchanged for new warrants pursuant to the terms of the offer. The aggregate value of such warrants was calculated based on the Black-Scholes pricing model.

x Check the box if any part of the fee is offset as provided by Rule 0-11(a)(2) and identify the filing with which the offsetting fee was previously paid. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.

Amount Previously Paid: \$1,948.35  
Form or Registration No.: 005-85686

Filing Party: InVivo Therapeutics Holdings Corp.  
Date Filed: April 8, 2013

.. Check the box if the filing relates solely to preliminary communications made before the commencement of a tender offer.  
Check the appropriate boxes below to designate any transactions to which the statement relates:

Edgar Filing: INVIVO THERAPEUTICS HOLDINGS CORP. - Form SC TO-I/A

- third-party tender offer subject to Rule 14d-1.
- issuer tender offer subject to Rule 13e-4.
- going-private transaction subject to Rule 13e-3.
- amendment to Schedule 13D under Rule 13d-2.

Check the following box if the filing is a final amendment reporting the results of the tender offer:

This Amendment No. 4 (this Amendment) amends and supplements the Tender Offer Statement on Schedule TO originally filed with the U.S. Securities and Exchange Commission (the SEC) by InVivo Therapeutics Holdings Corp., a Nevada corporation (the Company or InVivo), on April 8, 2013, as amended by Amendment No. 1 to Schedule TO filed with the SEC on April 26, 2013, Amendment No. 2 to Schedule TO filed with the SEC on May 3, 2013 and Amendment No. 3 to Schedule TO filed with the SEC on May 10, 2013 (as amended, the Schedule TO), in connection with the offer by the Company to exchange certain of its outstanding warrants to purchase common stock (the Original Warrants) for new warrants (the New Warrants) with the same terms except (i) the expiration date of the New Warrants will be extended two years and (ii) weighted average anti-dilution provisions will be removed from the New Warrants. The offer is subject to the terms and conditions set forth in the Offer to Exchange, dated April 8, 2013, a copy of which was filed with the Schedule TO as Exhibit (a)(1)(A) (the Offer to Exchange), and in the Election to Participate, a copy of which was filed with the Schedule TO as Exhibit (a)(1)(B) (the Election to Participate), which together with the Offer to Exchange, as each may be amended and supplemented from time to time, constitute the Offer (the Offer).

This Amendment No. 4 is being filed to report the final results of the Offer.

The information contained in the Offer to Exchange and the Election to Participate is incorporated herein by reference, except that such information is hereby amended and supplemented to the extent specifically provided herein.

#### Items 1 through 11

The information set forth in the Offer to Exchange is hereby amended and supplemented as follows:

The Offer expired at 11:59 p.m. (Eastern Time) on May 17, 2013. In connection with the Offer, all remaining Eligible Warrants to purchase shares of the Company's common stock were tendered and accepted for exchange for New Warrants, consisting of (i) Merger Warrants exercisable to purchase 255,000 shares of the Company's common stock and (ii) Placement Agent Warrants exercisable to purchase 3,064,091 shares of the Company's common stock. The Merger Warrants and Placement Agent Warrants tendered for exchange and accepted have been cancelled and the Company will issue New Warrants promptly.

#### Item 12. Exhibits.

- (a)(1)(A) \* Offer to Exchange, dated April 8, 2013, as amended on April 26, 2013 as reflected in Amendment No. 1 filed with the SEC on April 26, 2013 and on May 3, 2013 as reflected in Amendment No. 1 filed with the SEC on May 3, 2013
- (a)(1)(B) \* Election to Participate, as amended on April 26, 2013 as reflected in Amendment No. 1 filed with the SEC on April 26, 2013
- (a)(1)(C) \* Notice of Withdrawal
- (a)(1)(D) \* Form of New Warrants to be Exchanged for Eligible Warrants

- (a)(1)(E) \* Letter from Frank Reynolds, Chairman, Chief Executive Officer and Chief Financial Officer of the Company, to Holders of Eligible Warrants dated April 8, 2013
- (a)(1)(F) \* Press release dated April 8, 2013
- (a)(1)(G) \* Transcript of Company Webcast dated April 8, 2013
- (a)(1)(H) \* Press release dated May 3, 2013 announcing termination of Offer with respect to Investor Warrants
- (d)(1)(A) Form of Investor Warrant of InVivo Therapeutics Holdings Corp. (incorporated by reference from Exhibit 4.3 to the Company's Current Report on Form 8-K, as filed with the SEC on November 1, 2010)
- (d)(1)(B) Form of Warrant of InVivo Therapeutics Holdings Corp. issued to Bridge Lenders (incorporated by reference from Exhibit 4.5 to the Company's Current Report on Form 8-K, as filed with the SEC on November 1, 2010)
- (d)(1)(C) Form of Warrant of InVivo Therapeutics Holdings Corp. (\$1.00 exercise price) issued to Placement Agent (incorporated by reference from Exhibit 4.2 to the Company's Current Report on Form 8-K, as filed with the SEC on December 9, 2010)
- (d)(1)(D) Form of Warrant of InVivo Therapeutics Holdings Corp. (\$1.40 exercise price) issued to Placement Agent (incorporated by reference from Exhibit 4.3 to the Company's Current Report on Form 8-K, as filed with the SEC on December 9, 2010)
- (d)(1)(E) Form of Registration Rights Agreement, by and between InVivo Therapeutics Holdings Corp. and the investors in the offering (incorporated by reference from Exhibit 10.4 to the Company's Current Report on Form 8-K, as filed with the SEC on November 1, 2010)
- (d)(1)(F) Placement Agent Agreement dated October 4, 2010, between InVivo Therapeutics Corp. and Placement Agent (incorporated by reference from Exhibit 10.4 to the Company's Current Report on Form 8-K, as filed with the SEC on December 9, 2010)
- (d)(1)(E) Form of Registration Rights Agreement, by and between InVivo Therapeutics Holdings Corp. and the investors in the offering (incorporated by reference from Exhibit 10.4 to the Company's Current Report on Form 8-K, as filed with the SEC on November 1, 2010)
- (d)(1)(G) Placement Agent Agreement dated October 4, 2010, between InVivo Therapeutics Corp. and Placement Agent (incorporated by reference from Exhibit 10.4 to the Company's Current Report on Form 8-K, as filed with the SEC on December 9, 2010)

\* Previously filed.

SIGNATURE

After due inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

INVIVO THERAPEUTICS HOLDINGS CORP.

By: /s/ Frank M. Reynolds  
Name: Frank M. Reynolds  
Title: Chief Executive Officer

Date: May 20, 2013